A clinical study assessing STP355 for colorectal cancer and melanoma
Latest Information Update: 25 May 2022
Price :
$35 *
At a glance
- Drugs STP 355 (Primary)
- Indications Colorectal cancer; Malignant melanoma
- Focus Adverse reactions
- Sponsors Sirnaomics
- 25 May 2022 New trial record
- 20 May 2022 According to Sirnaomics media release, the Company intends to file IND to initiate this clinical study in 2023